Fujian Cancer Hospital: Adenocarcinoma trials

The registry lists 11 Adenocarcinoma studies with Fujian Cancer Hospital as lead sponsor. 0 are open to participants now and 0 have results posted.

Phase 1 1Phase 2 6Phase 3 1No phase 3(a study in two phases counts in both)

Studies

Open to participants first, then studies with results posted, then the rest; newest registration first within each.

• Serplulimab Combined With Anti-VEGF Antibody in Advanced Lung AdenocarcinomaStatus unknownNCT05675033Phase 2
• Study of FMT Combined With Nivolumab in Gastric CancerWithdrawnNCT05001360Not applicable
• PD-1 Antibody(SHR-1210) Plus Apatinib Combined With POF in Advanced Gastric CancerStatus unknownNCT04174339Not applicable
• Study of the Apatinib Combine With POF Versus POF in Gastric CancerStatus unknownNCT04121039Phase 2
• Apatinib Combined With POF for Second-line Treatment of Gastric AdenocarcinomaStatus unknownNCT03788174Phase 2
• Bevacizumab Plus Capecitabin vs S-1 as Maintenance Treatment Following First-line Chemotherapy in the Patients With Advanced Colorectal AdenocarcinomaWithdrawnNCT03708536Phase 3
• Study of the Combination of Apatinib and POFStatus unknownNCT03707639Phase 2
• Gefitinib and Berberine in the First-line Treatment of Lung Adenocarcinoma With EGFR MutationStatus unknownNCT03486496Phase 2
• Phase I Study of the Combination of Apatinib and POFStatus unknownNCT03244774Phase 1
• mFOLFOX Versus mFOLFIRI Versus FOLFPTX as First-line Treatment in AGC or EGJAStatus unknownNCT03045770Not applicable
• Clinical Trial to Compare Apatinib Plus Irinotecan Versus Single Irinotecan as Second-line Treatment in AGC or EGJAStatus unknownNCT03030937Phase 2